Of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000, 21(18):1502?513. Kida D, YM Miyaura S, Ishimaru T, Yoshida Y, Ito T, Ishiguro N, Iwata H, Kimata K: The SHAP-HA complex in sera from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 1999, 26:1230?238. Yingsung W, Zhuo L, Morgelin M, Yoneda M, Kida T, Watanabe H, Ishiguro N, Iwata H, Kimata K: Molecular heterogeneity of the SHAP-hyaluronan complex. Isolation and characterization of the complex in synovial fluid from patients with rheumatoid arthritis. J Biol Chem 2003, 278:32710?2718. Rhee SG, Woo HA, Kil IS, Bae SH: Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. J Biol Chem 2012, 287(7):4403?410. Lee TH, Kim SU, Yu SL, Kim SH, Park DS, Moon HB, Dho SH, Kwon KS, Kwon HJ, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/21715270 Han YH, Jeong S, Kang SW, Shin HS, Lee KK, Rhee SG, Yu DY: Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. Blood 2003, 101(12):5033?038. Miller YI, Smith A, Morgan WT, Shaklai N: Role of hemopexin in protection of low-density lipoprotein against hemoglobin-induced oxidation. Biochemistry 1996, 35(40):13112?3117. Miller YI, Altamentova SM, Shaklai N: Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: antioxidant role of haptoglobin. Biochemistry 1997, 36(40):12189?2198. Grinshtein N, Bamm VV, Tsemakhovich VA, Shaklai N: Mechanism of lowdensity lipoprotein oxidation by hemoglobin-derived iron. Biochemistry 2003, 42(23):6977?985. Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS: Relationship between serum copper, ceruloplasmin, and non-ceruloplasmin-bound copper in routine PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/3081428 clinical practice. Clin Chem 2005, 51(8):1558?559. Chao J, Stallone JN, Liang YM, Chen LM, Wang DZ, Chao L: Kallistatin is a potent new vasodilator. J Clin Invest 1997, 100:11?7. Miao RQ, Agata J, Chao L, Chao J: Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002, 100:3245?252. Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, Chao L, Chao J: Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 2005, 52:1319?324. Steinmetz A, Barbaras R, Ghalim N, Clavey V, Fruchart JC, Ailhaud G: Human apolipoprotein A-IV binds to 2-Chloro-5,6-dihydro-7H-cyclopenta[b]pyridin-7-one apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem 1990, 265:7859?863. Paszty C, Maeda N, Verstuyft J, Rubin EM: Apolipoprotein AI Ethyl (4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbamate hydrochloride transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994, 94:899?03. Plump AS, Scott CJ, Breslow JL: Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E- deficient mouse. Proc Natl Acad Sci U S A 1994, 91:9607?611. Ostos MA, Conconi M, Vergnes L, Baroukh N, Ribalta J, Girona J, Caillaud JM, Ochoa A, Zakin MM: Antioxidative and antiatherosclerotic effects of27. 28.29.30.31.32.33.34.35.36.37.38. 39.40. 41.human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:1023?028. Smith JD: Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr Opin Investig Drugs 2010, 11(9):989?96. Colman RW, Schmaier AH: Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive and proinflammatory attributes. Blood 1997, 90:3819?843. Isordia-Salas I, Sainz IM, Pixley RA, Martine.